Related Experiment Video

Updated: May 22, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

C1GALT1 polymorphisms are associated with Henoch-Schönlein purpura nephritis

Xuelian He1, Peiwei Zhao, Shixiu Kang

  • 1Wuhan Children's Hospital, No. 100 Hongkong Rd, Jiangan District, Wuhan, PR China. hxljm07@hotmail.com

Pediatric Nephrology (Berlin, Germany)
|May 1, 2012
PubMed

Insights

Genetic variations in the C1GALT1 gene, specifically the 1365 G/A polymorphism, are linked to an increased risk of developing Henoch-Schönlein purpura nephritis (HSPN). This finding sheds light on the genetic factors influencing HSPN susceptibility.

Area of Science:

  • Genetics
  • Immunology
  • Nephrology

Background:

  • Henoch-Schönlein purpura nephritis (HSPN) is a severe complication of Henoch-Schönlein purpura (HSP).
  • Aberrant galactosylation of IgA1 is implicated in HSPN pathogenesis.
  • The genetic underpinnings of abnormal IgA1 galactosylation in HSPN remain largely unknown.

Purpose of the Study:

  • To investigate the association between the C1GALT1 gene, encoding core 1 β1,3-galactosyltransferase, and susceptibility to HSPN.
  • To explore the role of specific single nucleotide polymorphisms (SNPs) within the C1GALT1 gene in HSPN development.

Main Methods:

  • A case-control genetic association study was conducted in China.
  • 269 patients with HSP and 61 with HSPN were analyzed.
  • Five tagging SNPs in the C1GALT1 gene were genotyped and analyzed using single-locus and haplotype-based approaches.

Main Results:

  • The 1365 G allele of the C1GALT1 gene was significantly more frequent in HSPN patients compared to HSP patients without nephritis (p = 0.0008).
  • The GG genotype at the 1365 G/A locus showed a significant difference between HSP without nephritis and HSPN groups (p = 0.008).
  • No statistically significant differences in haplotype frequencies were observed between the groups.

Conclusions:

  • The 1365 G/A polymorphism in the C1GALT1 gene is suggested to be a potential genetic risk factor for HSPN development.
  • This finding contributes to understanding the genetic basis of aberrant IgA1 glycosylation in HSPN.
Abstract

More Related Videos

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...